These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 11036049)

  • 1. In vitro susceptibilities of Capnocytophaga isolates to beta-lactam antibiotics and beta-lactamase inhibitors.
    Jolivet-Gougeon A; Buffet A; Dupuy C; Sixou JL; Bonnaure-Mallet M; David S; Cormier M
    Antimicrob Agents Chemother; 2000 Nov; 44(11):3186-8. PubMed ID: 11036049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro activities of the beta-lactamase inhibitors clavulanic acid, sulbactam, and tazobactam alone or in combination with beta-lactams against epidemiologically characterized multidrug-resistant Acinetobacter baumannii strains.
    Higgins PG; Wisplinghoff H; Stefanik D; Seifert H
    Antimicrob Agents Chemother; 2004 May; 48(5):1586-92. PubMed ID: 15105109
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antimicrobial susceptibilities of Campylobacter jejuni and Campylobacter coli to 12 beta-lactam agents and combinations with beta-lactamase inhibitors.
    Tajada P; Gomez-Graces JL; Alós JI; Balas D; Cogollos R
    Antimicrob Agents Chemother; 1996 Aug; 40(8):1924-5. PubMed ID: 8843305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative evaluation of the in vitro activity of three combinations of beta-lactams with beta-lactamase inhibitors: piperacillin/tazobactam, ticarcillin/clavulanic acid and ampicillin/sulbactam.
    Sader HS; Tosin I; Sejas L; Miranda E
    Braz J Infect Dis; 2000 Feb; 4(1):22-8. PubMed ID: 10788842
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activity of beta-lactamase inhibitors against clinical isolates of Acinetobacter species.
    Suh B; Shapiro T; Jones R; Satishchandran V; Truant AL
    Diagn Microbiol Infect Dis; 1995 Feb; 21(2):111-4. PubMed ID: 7628190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tazobactam is a potent inactivator of selected inhibitor-resistant class A beta-lactamases.
    Bonomo RA; Rudin SA; Shlaes DM
    FEMS Microbiol Lett; 1997 Mar; 148(1):59-62. PubMed ID: 9066111
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative activity of beta-lactamase inhibitors YTR 830, clavulanate, and sulbactam combined with beta-lactams against beta-lactamase-producing anaerobes.
    Appelbaum PC; Jacobs MR; Spangler SK; Yamabe S
    Antimicrob Agents Chemother; 1986 Nov; 30(5):789-91. PubMed ID: 3026241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evolution of beta-lactamase inhibitors.
    Rolinson GN
    Rev Infect Dis; 1991; 13 Suppl 9():S727-32. PubMed ID: 1656513
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative in vitro activity of beta-lactam/beta-lactamase inhibitor combinations against gram negative bacteria.
    Mohanty S; Singhal R; Sood S; Dhawan B; Das BK; Kapil A
    Indian J Med Res; 2005 Nov; 122(5):425-8. PubMed ID: 16456257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activity of beta-lactamase inhibitors in combination with new beta-lactam antibiotics against resistant gram-negative organisms.
    Bolivar R; Weaver SS; Bodey GP
    Diagn Microbiol Infect Dis; 1984 Jun; 2(3):255-60. PubMed ID: 6086213
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Penicillins and beta-lactamase inhibitor combinations.
    Mealey KL
    J Am Vet Med Assoc; 2001 Jun; 218(12):1893-6. PubMed ID: 11417732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activity of 13 beta-lactam agents combined with BRL 42715 against beta-lactamase producing gram-negative bacteria compared to combinations with clavulanic acid, tazobactam and sulbactam.
    Piddock LJ; Jin YF; Turner HL
    J Antimicrob Chemother; 1993 Jan; 31(1):89-103. PubMed ID: 8383105
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In-vitro evaluation of the four beta-lactamase inhibitors: BRL42715, clavulanic acid, sulbactam, and tazobactam.
    Muratani T; Yokota E; Nakane T; Inoue E; Mitsuhashi S
    J Antimicrob Chemother; 1993 Sep; 32(3):421-9. PubMed ID: 8262864
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Susceptibility of clinical isolates to expanded-spectrum beta-lactams alone and in the presence of beta-lactamase inhibitors.
    Qadri SM; Ueno Y; Cunha BA
    Chemotherapy; 1996; 42(5):334-42. PubMed ID: 8874972
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cross-resistance to beta-lactam-beta-lactamase inhibitor combinations and clindamycin among cefoxitin-resistant and cefoxitin-susceptible strains of the Bacteroides fragilis group.
    Aldridge KE
    Diagn Microbiol Infect Dis; 1993 Oct; 17(3):251-6. PubMed ID: 8112038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Susceptibilities of beta-lactamase-positive and -negative strains of Campylobacter coli to beta-lactam agents.
    Lachance N; Gaudreau C; Lamothe F; Turgeon F
    Antimicrob Agents Chemother; 1993 May; 37(5):1174-6. PubMed ID: 8390812
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sensitivity pattern of gram negative bacilli to three beta-lactam/beta-lactamase inhibitor combinations using the automated API system.
    Anuradha K; Sailaja VV; Umabala P; Satheesh T; Lakshmi V
    Indian J Med Microbiol; 2007 Jul; 25(3):203-8. PubMed ID: 17901635
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In-vitro susceptibilities of species of the Bacteroides fragilis group to newer beta-lactam agents.
    Betriu C; Sánchez A; Gómez M; Palau ML; Picazo JJ
    J Antimicrob Chemother; 1999 Jan; 43(1):133-6. PubMed ID: 10381111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The effectiveness of so-called potentiated penicillins (augmentin and tazobactam) in vitro].
    Blahová J; Hupková M; Krcméry V
    Cas Lek Cesk; 1995 Sep; 134(17):558-61. PubMed ID: 7553760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Susceptibilities of ESBL-producing Enterobacteriaceae to ertapenem, meropenem and piperacillin-tazobactam with and without clavulanic acid.
    Raveh D; Yinnon AM; Broide E; Rudensky B
    Chemotherapy; 2007; 53(3):185-9. PubMed ID: 17347564
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.